Jacobs Levy Equity Management Inc. Sells 2,042,706 Shares of Ironwood Pharmaceuticals, Inc. $IRWD

Key Points

• Jacobs Levy Equity Management Inc. has significantly reduced its stake in Ironwood Pharmaceuticals by 56.4%, selling over 2 million shares in the first quarter, leaving it with a total of approximately 1.58 million shares valued at around $2.32 million.
• Brokerages have shown mixed sentiments on Ironwood Pharmaceuticals, with Zacks Research downgrading the stock from "strong buy" to "hold" while Wall Street Zen upgraded it to "strong buy," resulting in a consensus rating of "Hold" with an average target price of $4.94.
• Ironwood Pharmaceuticals reported a quarterly revenue of $85.24 million, significantly above consensus estimates of $62.02 million, along with earnings per share of $0.14, beating estimates by $0.16.

Jacobs Levy Equity Management Inc. reduced its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 56.4% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,580,320 shares of the biotechnology company's stock after selling 2,042,706 shares during the period. Jacobs Levy Equity Management Inc. owned 0.98% of Ironwood Pharmaceuticals worth $2,323,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Deutsche Bank AG lifted its holdings in Ironwood Pharmaceuticals by 47.4% during the fourth quarter. Deutsche Bank AG now owns 1,567,535 shares of the biotechnology company's stock worth $6,944,000 after acquiring an additional 504,336 shares in the last quarter. GSA Capital Partners LLP increased its position in shares of Ironwood Pharmaceuticals by 3,683.6% in the first quarter. GSA Capital Partners LLP now owns 524,676 shares of the biotechnology company's stock valued at $771,000 after acquiring an additional 510,809 shares during the last quarter. Armistice Capital LLC increased its position in Ironwood Pharmaceuticals by 44.7% during the first quarter. Armistice Capital LLC now owns 13,700,000 shares of the biotechnology company's stock worth $20,139,000 after buying an additional 4,232,000 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Ironwood Pharmaceuticals during the fourth quarter worth approximately $1,888,000. Finally, Cerity Partners LLC acquired a new position in Ironwood Pharmaceuticals during the first quarter worth approximately $142,000.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on IRWD. Wall Street Zen upgraded Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Zacks Research downgraded Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, September 5th. One investment analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $4.94.

Ironwood Pharmaceuticals Stock Up 1.6%

Shares of NASDAQ:IRWD traded up $0.02 during midday trading on Tuesday, hitting $1.30. 662,337 shares of the stock traded hands, compared to its average volume of 1,211,235. Ironwood Pharmaceuticals, Inc. has a one year low of $0.53 and a one year high of $5.13. The business's 50 day moving average is $1.00 and its two-hundred day moving average is $0.96. The stock has a market capitalization of $211.16 million, a PE ratio of -25.99 and a beta of 0.33.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.16. Ironwood Pharmaceuticals had a negative net margin of 2.25% and a negative return on equity of 2.46%. The company had revenue of $85.24 million for the quarter, compared to analysts' expectations of $62.02 million. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.